NPS Pharma's Gattex Picked by Providers to Support Distribution, Home-Based Clinical Care Services

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical companypioneering and delivering therapies that transform the lives of patients withrare diseases worldwide, today announced that it has established apatient-centric distribution and clinical service network for Gattex^(Teduglutide [rDNA origin]) for Injection, for subcutaneous use. The networkis comprised of leading specialty home infusion providers, including AccredoHealth Group, Inc.; BioScrip; Inc.; Coram, LLC; ThriveRx; and WalgreensInfusion Services. In addition to dispensing Gattex, the company's contractedproviders will provide clinical services to support the use of Gattex inreducing dependence on parenteral nutrition (PN) and intravenous fluids (IV)for patients with short bowel syndrome (SBS). Gattex was approved by the U.S.Food and Drug Administration (FDA) on December 21, 2012 as a treatment foradults with SBS who are dependent on parenteral support. Gattex is thefirst-and-only FDA-approved therapy for the long-term treatment of SBS and thefirst major treatment advance for SBS in nearly 40 years.

By adding Gattex to their product offering the company's contracted homeinfusion providers will offer a wide range of personalized services toPN-dependent patients with short bowel syndrome through an interdisciplinaryteam of experienced infusion professionals, including nurses, pharmacists,dietitians, and support professionals.